Chemical name: 2,2′-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile)
Formula: C17H19N5

1. Introduction: Antreol-1 is a medication manufactured by Knoll Healthcare, containing the active substance Anastrozole. It is primarily used in the treatment of hormone receptor-positive breast cancer, particularly in postmenopausal women.

2. Mechanism of Action: Anastrozole, the active ingredient in Antreol-1, is a selective aromatase inhibitor. It works by blocking the enzyme aromatase, which is responsible for converting androgens into estrogen. By inhibiting estrogen production, Anastrozole helps to reduce estrogen levels in the body, thereby slowing down the growth of estrogen-dependent breast tumors.

3. Indications: Antreol-1 (Anastrozole 1 mg Tablets) is indicated for:

• Breast Cancer: Treatment of hormone receptor-positive breast cancer in postmenopausal women, either as initial adjuvant therapy, following surgery or radiation, or in the treatment of advanced disease.

4. Dosage and Administration: The recommended dosage of Antreol-1 may vary depending on the specific condition being treated, disease stage, and individual patient factors. It is typically taken orally as a tablet, usually once a day, with or without food.

5. Monitoring and Side Effects: Patients taking Antreol-1 may undergo regular monitoring, including clinical assessments and imaging studies, to evaluate the medication’s effectiveness and detect any potential side effects. Common side effects may include hot flashes, joint pain, fatigue, headache, and nausea. Serious side effects, such as bone thinning (osteoporosis) and increased risk of cardiovascular events, may occur but are less common.

6. Precautions: Antreol-1 should be used with caution in patients with a history of osteoporosis, cardiovascular disease, or liver dysfunction. It may increase the risk of bone fractures and cardiovascular events, and patients should be monitored closely for these complications during treatment.

7. Interactions: Anastrozole may interact with other medications, including hormone replacement therapy, tamoxifen, and certain anticoagulants. Patients should inform their healthcare provider about all medications, supplements, and herbal products they are taking to avoid potential interactions.

8. Pregnancy and Breastfeeding: Antreol-1 is contraindicated in pregnant or breastfeeding women due to the potential for fetal harm. Women of childbearing potential should use effective contraception during treatment and for a period after discontinuation.

9. Duration of Treatment: The duration of treatment with Antreol-1 (Anastrozole 1 mg Tablets) varies depending on the individual’s response to therapy, disease progression, and treatment goals. Healthcare providers will determine the appropriate duration and may adjust the treatment plan based on ongoing assessments of disease status and side effects.

10. Conclusion: Antreol-1 (Anastrozole 1 mg Tablets) manufactured by Knoll Healthcare is an essential medication used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. Its mechanism of action as a selective aromatase inhibitor provides effective suppression of estrogen levels, helping to slow down the growth of estrogen-dependent tumors. Patients prescribed Antreol-1 should closely follow their healthcare provider’s instructions, undergo regular monitoring, and report any concerns or side effects promptly to ensure optimal treatment outcomes.